Paper Details

  1. Home
  2. Paper Details

Management of ER positive metastatic breast cancer.

Author: FinnRichard S, McAndrewNicholas P

ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

This article reviews the therapeutic landscape of advanced estrogen receptor-positive (ER+) breast cancer, highlighting the evolution of treatment from single-agent endocrine therapy to combination approaches. Recent advances include the FDA approval of mTOR inhibitors, CDK 4/6 inhibitors, and PI3-kinase inhibitors, expanding treatment options and improving outcomes for patients with advanced ER+ breast cancer.
Paper Details　
Original Abstract of the Article :
There are over 2 million cases a year of breast cancer, leading to over 600,000 deaths globally [1]. Despite these large numbers, increasingly more women are being cured with early stage disease and women with advanced disease are living longer [2]. The appreciation for molecular subtypes of the dis...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1053/j.seminoncol.2020.07.005

データ提供：米国国立医学図書館（NLM）

Management of ER Positive Metastatic Breast Cancer

Breast cancer is a complex and challenging disease, but significant advances have been made in recent years. This review explores the management of estrogen receptor-positive (ER+) metastatic breast cancer, the most common subtype of the disease.

Targeting Estrogen Signaling in ER+ Breast Cancer

The authors provide a comprehensive overview of the evolution of treatment for ER+ breast cancer, from early hormonal therapies to the development of new drugs that target specific pathways involved in tumor growth. They highlight the importance of understanding the role of estrogen signaling in ER+ breast cancer and the progress made in developing therapies that effectively block or modify this signaling.

New Hope for ER+ Metastatic Breast Cancer

This review provides a hopeful outlook for patients with ER+ metastatic breast cancer. The development of new drugs, such as mTOR inhibitors, CDK 4/6 inhibitors, and PI3-kinase inhibitors, has led to improved efficacy and longer survival times. While the disease is incurable, these advances offer greater control over the disease and a better quality of life for patients.

Dr. Camel's Conclusion

This review emphasizes the significant progress made in the management of ER+ metastatic breast cancer. Like a camel navigating a challenging desert landscape, finding the right treatment strategies is essential for managing this complex disease. The development of new and targeted therapies offers hope for a future where patients with ER+ metastatic breast cancer can live longer and healthier lives.

Date :
  1. Date Completed 2021-01-25
  2. Date Revised 2021-01-25
Further Info :

Pubmed ID

32958261

DOI: Digital Object Identifier

10.1053/j.seminoncol.2020.07.005

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.